Insider Transactions Reported by 28 Insiders of Calidi Biotherapeutics, Inc.

Symbol: CLDI on NYSE, CLDWW on OTC
Location: San Diego, CA

Quick Takeaways

CLDI - Calidi Biotherapeutics, Inc. has 28 insiders with reported activity on this page.
Net insider value flow over the last year: -$1,237.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $1,236.
Net share flow: <span class="text-red-600">-850</span>.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$1,237.

Buys

Shares: 0

Insiders: 0

Sells

$1,237

Shares: 850

Insiders: 1

Net

-$1,237

Shares: -850

Insiders: -1

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	850	$0	$1,237	+$1,237
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

Calidi Biotherapeutics, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Polar Asset Management Partners Inc.	10%+ Owner	$4,330,272			Mixed	19 Oct 2022
Stephen Thesing	Chief Business Officer	$848,779			Mixed	12 Sep 2023
Boris Radoslavov Minev	Interim Chief Medical Officer	$764,024			Mixed	17 Jun 2024
Thomas A. Vecchiolla	Director	$657,189			Mixed	21 Dec 2023
Tony T. Kalajian	Chief Acctg Officer, Int. CFO	$501,822			Mixed	12 Sep 2023
Heehyoung Lee	Director, Former Director	$444,096			Mixed	10 Oct 2023
Lincoln Alternative Strategies LLC	10%+ Owner	$430,700			Mixed	20 Aug 2025
Wendy Pizarro Campbell	Chief Admin. and Legal Officer	$292,273			Mixed	17 Jun 2024
Alfonso G. Zulueta	Director	$239,942			Mixed	21 Dec 2023
Allan Camaisa	Director	$111,965	-$1,237	-1.1%	Filing P/S	12 Dec 2025
Scott Leftwich	Director	$86,511			Mixed	21 Aug 2025
Amish Patel	VP of Technical Operations	$52,745			Mixed	12 Sep 2023
George K. Ng	Director	$50,566			Mixed	12 Sep 2023
James A. Schoeneck	Director	$49,862			Mixed	21 Aug 2025
Alan R. Stewart	Director	$46,941			Mixed	09 Jul 2025
David Sans	Chief of Corporate Development	$32,965			Mixed	12 Sep 2023
Eric E. Poma	Chief Executive Officer	$14,750			Mixed	03 Sep 2025
Andrew C. Jackson	Chief Financial Officer	$1,475			Mixed	03 Sep 2025
Antonio Fernandez Santidrian	Chief Scientific Officer				Mixed	03 Sep 2025
George Peoples	Director				Mixed	09 Jul 2025
David LaPre	Director				Mixed	01 Jan 2024
Michael J. Alber	Chief Financial Officer				Mixed	09 Sep 2021
Hudson Bay Capital Management LP	10%+ Owner				Mixed	12 Sep 2023
Michael C. Ruettgers	Director				Mixed	09 Sep 2021
Jeanne Tisinger	Director				Mixed	09 Sep 2021
William John Weber	Chief Executive Officer, Director, 10%+ Owner				Mixed	09 Sep 2021
William J. Fallon	Director				Mixed	09 Sep 2021
First Light Acquisition Group, LLC	10%+ Owner				Mixed	16 Jun 2023

Top shareholders of Calidi Biotherapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Polar Asset Management Partners Inc.	3/4/5	10%+ Owner	— class O/S missing	412,800	$4,330,272	—	19 Oct 2022	3/4/5
Stephen Thesing	3/4/5	Chief Business Officer	— class O/S missing	471,544	$848,779	—	12 Sep 2023	3/4/5
Boris Radoslavov Minev	3/4/5	Interim Chief Medical Officer	— mixed-class rows	455,818 mixed-class rows	$764,024	—	17 Jun 2024	3/4/5
Thomas A. Vecchiolla	3/4/5	Director	— mixed-class rows	781,459 mixed-class rows	$657,189	—	21 Dec 2023	3/4/5
Tony T. Kalajian	3/4/5	Chief Acctg Officer, Int. CFO	— class O/S missing	278,790	$501,822	—	12 Sep 2023	3/4/5
Heehyoung Lee	3/4/5	Director, Former Director	— class O/S missing	246,720	$444,096	—	10 Oct 2023	3/4/5
Lincoln Alternative Strategies LLC	3/4/5	10%+ Owner	2.2%	730,000	$430,700	—	20 Aug 2025	3/4/5
Wendy Pizarro Campbell	3/4/5	Chief Admin. and Legal Officer	— mixed-class rows	222,374 mixed-class rows	$292,273	—	17 Jun 2024	3/4/5
Alfonso G. Zulueta	3/4/5	Director	— class O/S missing	133,301	$239,942	—	21 Dec 2023	3/4/5
DRW Securities, LLC	13F	Company	2.1%	147,767	$172,887	—	31 Dec 2025	13F
Allan Camaisa	3/4/5	Director	1.1%	76,952	$111,965	-$1,237	12 Dec 2025	3/4/5
HighTower Advisors, LLC	13F	Company	1.2%	83,523	$97,722	—	31 Dec 2025	13F
Scott Leftwich	3/4/5	Director	— mixed-class rows	408,709 mixed-class rows	$86,511	—	21 Aug 2025	3/4/5
Amish Patel	3/4/5	VP of Technical Operations	— class O/S missing	29,303	$52,745	—	12 Sep 2023	3/4/5
George K. Ng	3/4/5	Director	— class O/S missing	28,092	$50,566	—	12 Sep 2023	3/4/5
James A. Schoeneck	3/4/5	Director	— mixed-class rows	324,007 mixed-class rows	$49,862	—	21 Aug 2025	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.59%	41,929	$49,056	—	31 Dec 2025	13F
Alan R. Stewart	3/4/5	Director	— mixed-class rows	166,054 mixed-class rows	$46,941	—	09 Jul 2025	3/4/5
VANGUARD GROUP INC	13F	Company	0.49%	34,728	$40,632	—	31 Dec 2025	13F
David Sans	3/4/5	Chief of Corporate Development	— class O/S missing	18,314	$32,965	—	12 Sep 2023	3/4/5
FMR LLC	13F	Company	0.31%	22,013	$25,755	—	31 Dec 2025	13F
Virtu Financial LLC	13F	Company	0.3%	21,243	$25,000	—	31 Dec 2025	13F
RS CRUM INC.	13F	Company	0.28%	20,256	$23,700	—	31 Dec 2025	13F
Belpointe Asset Management LLC	13F	Company	0.28%	19,971	$23,366	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.25%	17,758	$20,777	—	31 Dec 2025	13F
Eric E. Poma	3/4/5	Chief Executive Officer	— mixed-class rows	786,412 mixed-class rows	$14,750	—	03 Sep 2025	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.16%	11,491	$13,444	—	31 Dec 2025	13F
Farther Finance Advisors, LLC	13F	Company	0.14%	10,000	$11,700	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.11%	7,514	$8,792	—	31 Dec 2025	13F
Gavrilov Ognian Anguelov	13D/G	—	0.3%	20,000	$6,600	-$224,400	31 Mar 2026	13D/G
Tower Research Capital LLC (TRC)	13F	Company	0.04%	2,774	$3,246	—	31 Dec 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.03%	2,106	$2,463	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.02%	1,467	$1,716	—	31 Dec 2025	13F
Andrew C. Jackson	3/4/5	Chief Financial Officer	— mixed-class rows	35,000 mixed-class rows	$1,475	—	03 Sep 2025	3/4/5
Apollo Management Holdings, L.P.	13F	Company	0.01%	1,042	$1,219	—	31 Dec 2025	13F
Finepoint Capital LP	13F	Company	0.01%	1,042	$1,219	—	31 Dec 2025	13F
HIGHBRIDGE CAPITAL MANAGEMENT LLC	13F	Company	0.01%	1,042	$1,218	—	31 Dec 2025	13F
BARRETT & COMPANY, INC.	13F	Company	0%	292	$342	—	31 Dec 2025	13F
Tradewinds Capital Management, LLC	13F	Company	0%	101	$119	—	31 Dec 2025	13F
Reyes Financial Architecture, Inc.	13F	Company	0%	100	$117	—	31 Dec 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	46	$54	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	46	$53	—	31 Dec 2025	13F
CVA Family Office, LLC	13F	Company	0%	42	$49	—	31 Dec 2025	13F
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	13F	Company	0%	28	$33	—	31 Dec 2025	13F
EVERMAY WEALTH MANAGEMENT LLC	13F	Company	0%	1	$2	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0%	1	$1	—	31 Dec 2025	13F
First Light Acquisition Group, LLC	3/4/5	10%+ Owner	— class O/S missing	1,931,852	—	—	16 Jun 2023	3/4/5
George Peoples	3/4/5	Director	— class O/S missing	137,078	—	—	09 Jul 2025	3/4/5
ARMISTICE CAPITAL, LLC	13D/G	—	5%	117,368	—	$0	30 Jun 2025	13D/G
Antonio Fernandez Santidrian	3/4/5	Chief Scientific Officer	— class O/S missing	35,000	—	—	03 Sep 2025	3/4/5

Recent Insider Transactions by Companies or Individuals for Calidi Biotherapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Allan Camaisa	CLDI	Common Stock	Sale	-1.09%	$1,237	$1.46	-850	76,952	12 Dec 2025	AJC Capital, LLC
Eric E. Poma	CLDI	Stock Options (right to buy)	Award				10,000	10,000	03 Sep 2025	Direct
Antonio Fernandez Santidrian	CLDI	Stock Options (right to buy)	Award				35,000	35,000	03 Sep 2025	Direct
Andrew C. Jackson	CLDI	Stock Options (right to buy)	Award				30,000	30,000	03 Sep 2025	Direct
James A. Schoeneck	CLDI	Common Stock	Purchase	6613.8%			75,000	76,134	21 Aug 2025	Direct
James A. Schoeneck	CLDI	Warrant (right to buy)	Purchase				75,000	75,000	21 Aug 2025	Direct
Eric E. Poma	CLDI	Common Stock	Purchase				25,000	25,000	21 Aug 2025	Direct
Eric E. Poma	CLDI	Warrant (right to buy)	Purchase				25,000	25,000	21 Aug 2025	Direct
Scott Leftwich	CLDI	Common Stock	Purchase	2212.4%			125,000	130,650	21 Aug 2025	Direct
Scott Leftwich	CLDI	Warrant (right to buy)	Purchase				125,000	125,000	21 Aug 2025	Direct
Andrew C. Jackson	CLDI	Common Stock	Purchase				2,500	2,500	21 Aug 2025	Direct
Andrew C. Jackson	CLDI	Warrant (right to buy)	Purchase				2,500	2,500	21 Aug 2025	Direct
James A. Schoeneck	CLDI	Non-Qualified Stock Options (right to buy)	Award				164,493	164,493	09 Jul 2025	Direct
Alan R. Stewart	CLDI	Non-Qualified Stock Options (right to buy)	Award				137,078	137,078	09 Jul 2025	Direct
George Peoples	CLDI	Non-Qualified Stock Options (right to buy)	Award				137,078	137,078	09 Jul 2025	Direct
Scott Leftwich	CLDI	Non-Qualified Stock Options (right to buy)	Award				137,078	137,078	09 Jul 2025	Direct
Eric E. Poma	CLDI	Stock Option (right to buy)	Award				726,412	726,412	22 Apr 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.